Biopharma News

Oct 18, 2018
By BioPharm International Editors
The companies will work together to develop Ionis-FB-LRx for the treatment of complement-mediated diseases, including Geographic Atrophy (GA), the advanced stage of dry age-related macular degeneration (AMD), in a deal worth $760 million.
Oct 17, 2018
By BioPharm International Editors
Amgen’s biosimilar to AbbVie’s Humira (adalimumab) is the first inflammation biosimilar from Amgen's portfolio to launch in Europe.
Oct 12, 2018
By BioPharm International Editors
Novartis’ Sandoz has reached a global patent resolution for Hyrimoz (adalimumab), its biosimilar to AbbVie’s Humira (adalimumab).
Oct 11, 2018
By BioPharm International Editors
Roche has acquired Tusk Therapeutics in a deal worth up to EUR 659 million (US$762 million).
Oct 10, 2018
By BioPharm International Editors
The companies signed a three-year clinical manufacturing agreement to manufacture GlaxoSmithKline’s specific peptide enhanced affinity receptor T-cell receptor therapy for United States, Canadian, and European clinical trials.
Oct 10, 2018
By BioPharm International Editors
The companies will develop and commercialize ARO-HBV, a Phase I/II subcutaneous, ribonucleic acid interference therapy candidate being investigated for the treatment of chronic hepatitis B viral infection.
Oct 04, 2018
By BioPharm International Editors
Insmed’s Arikayce (amikacin liposome inhalation suspension) is the first drug approved under the agency’s Limited Population Pathway for Antibacterial and Antifungal Drugs, established to support development of antibiotics for unmet medical needs.
Oct 03, 2018
By BioPharm International Editors
The companies will work together to discover, develop, and commercialize immunotherapies for patients with solid-tumor cancers in a collaboration worth $695 million per program.
Oct 01, 2018
By BioPharm International Editors
The divestiture of the European generic-drug business of Sanofi—Zentiva—to Advent International has been completed.
Oct 01, 2018
By BioPharm International Editors
Kangstem Biotech has selected Orgenesis subsidiary, MaSTherCell, as its contract manufacturing partner for the European clinical trial of Furestem-AD.
native1_300x100
lorem ipsum